Imagen de Portada

GLP‐1 receptor agonists and retained gastric content: Is it much ado about nothing?

Fuente: Wiley Open Access

Guardado en:

Detalles Bibliográficos
Autor principal:	Michael Camilleri
Formato:	Artículo Open Access
Publicado:	Wiley 2025
Materias:	Obesity
Acceso en línea:	Acceder al recurso
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Balancing procedural safety and therapeutic continuity: GLP‐1 receptor agonists and upper endoscopy
por: Lien‐Chung Wei, et al.
Publicado: (2025)

Less frequent dosing of GLP‐1 receptor agonists as a viable weight maintenance strategy
por: Calvin C. Wu, et al.
Publicado: (2025)

GLP ‐1 receptor agonists and cardiovascular events in metabolically healthy or unhealthy obesity
por: Tommaso Bucci, et al.
Publicado: (2025)

Healthcare professionals' perceptions and management of obesity & knowledge of glucagon, GLP‐1, GIP receptor agonists, and dual agonists
por: W. Timothy Garvey, et al.
Publicado: (2024)

Digital engagement enhances dual GIP / GLP ‐1 receptor agonist and GLP ‐1 receptor agonist efficacy: A retrospective cohort analysis of a digital weight loss service on outcomes and safety
por: Hans Johnson, et al.
Publicado: (2025)

Psychiatric effects of GLP ‐1 receptor agonists: A systematic review of emerging evidence
por: Brianna Sa, et al.
Publicado: (2025)

The extent and predictors of off‐label use of GLP ‐1 receptor agonists for weight loss management
por: Zbigniew Siudak, et al.
Publicado: (2025)

GLP ‐1 receptor agonists versus testosterone in male reproductive health: A critical perspective
por: João Oliveira Torres, et al.
Publicado: (2025)

Comparative healthcare resource utilization and costs of empagliflozin and GLP ‐1 receptor agonists in type 2 diabetes
por: Phyo Than Htoo, et al.
Publicado: (2025)

Beyond diabetes and obesity: GLP ‐1 receptor agonists in disrupting the vicious cycle of metabolic dysfunction and neuroinflammation
por: Renata Spezani, et al.
Publicado: (2025)

Cardiovascular and kidney outcomes of GLP ‐1 receptor agonists in adults with obesity: A target trial emulation study
por: Huilin Tang, et al.
Publicado: (2025)

Effectiveness and safety of GLP ‐1 receptor agonists in craniopharyngioma patients with obesity: A multicentre real‐world study
por: Flora Lambert, et al.
Publicado: (2025)

Highway to the danger zone? A cautionary account that GLP‐1 receptor agonists may be too effective for unmonitored weight loss
por: Jesse R. Richards, et al.
Publicado: (2024)

Potential role of glucagon like peptide (GLP)‐1 receptor agonist to reduce risk of colorectal cancer?
por: Iskandar Idris
Publicado: (2024)

Adherence to GLP ‐1 receptor agonists and SGLT2 inhibitors by out‐of‐pocket spending among Medicare beneficiaries with diabetes
por: Nicklas S. Klepser, et al.
Publicado: (2025)

GLP ‐1 receptor agonists for treating obesity without diabetes: A systematic review and meta‐analysis of economic evaluations
por: Teerapon Dhippayom, et al.
Publicado: (2025)

Sex differences in the efficacy of GLP ‐1 receptor agonists: A systematic review and meta‐analysis of cardiovascular and renal outcome trials
por: Hasan Fareed Siddiqui, et al.
Publicado: (2025)

Effects of GLP ‐1 receptor agonists on incidence and outcomes of ischemic stroke and myocardial infarction: A systematic review and meta‐analysis
por: Nawal Alammari, et al.
Publicado: (2025)

Glucagon‐like peptide 1 ( GLP ‐1) receptor agonists' use during pregnancy: Safety data from regulatory clinical trials
por: Claire H. Parker, et al.
Publicado: (2025)

Phase I study of the oral GLP ‐1 receptor agonist DA ‐ 302168S : Safety, pharmacokinetics, and pharmacodynamics in healthy and overweight/obese adults
por: Liang Zheng, et al.
Publicado: (2025)

Association of GLP1 ‐receptor agonist use with liver disease progression, major cardiovascular events, and mortality in people with hepatic steatosis and diabetes
por: Suleiman Al Ashi, et al.
Publicado: (2025)

The effect of GLP ‐1 receptor agonists on circulating inflammatory markers in type 2 diabetes patients: A systematic review and meta‐analysis
por: Yifan Ren, et al.
Publicado: (2025)

No causal link between the supply of GLP ‐1 receptor agonists and antidepressants: Real‐world evidence from the Australian Pharmaceutical Benefits Scheme
por: Osvaldo P. Almeida, et al.
Publicado: (2025)

The importance of treatment sequencing with SGLT2 inhibitors and GLP ‐1 receptor agonists combination for kidney function preservation in type 2 diabetes
por: Mario Luca Morieri, et al.
Publicado: (2026)

Efficacy and safety of GLP ‐1 receptor agonists and SGLT2 inhibitors as adjuncts to insulin in type 1 diabetes: Systematic review and meta‐analysis
por: Sama M. Abdel‐Rahman, et al.
Publicado: (2026)

Effectiveness of add‐on therapy with SGLT2 inhibitors or GLP ‐1 receptor agonists in adults with type 1 diabetes: A prospective DPV registry study
por: Christina Baechle, et al.
Publicado: (2024)

One‐year usage patterns of SGLT ‐2 inhibitors and GLP ‐1 receptor agonists in individuals with type 2 diabetes in a real‐world population
por: Louise A. Donnelly, et al.
Publicado: (2025)

Short‐term outcomes of switching from GLP ‐1 receptor agonists to tirzepatide in type 2 diabetes: A retrospective, observational study in clinical practice
por: Mari Matsushiro, et al.
Publicado: (2025)

Cardiorenal outcomes and mortality with GLP ‐1 receptor agonists combined with SGLT2 inhibitors in type 2 diabetes: An updated systematic review and meta‐analysis
por: João Sérgio Neves, et al.
Publicado: (2025)

Effects of GLP ‐1 receptor agonists on cognitive function in patients with type 2 diabetes: A systematic review and meta‐analysis based on randomized controlled trials
por: Suxin Wan, et al.
Publicado: (2025)

Risk of depression with GLP ‐1 receptor agonists use in overweight or obese adults with type 2 diabetes: A new‐user, active‐comparator cohort study
por: Yu Chang, et al.
Publicado: (2025)

Binding kinetics, bias, receptor internalization and effects on insulin secretion in vitro and in vivo of a novel GLP ‐ 1R / GIPR dual agonist, HISHS ‐2001
por: Yusman Manchanda, et al.
Publicado: (2025)

Efficacy of GLP ‐1 receptor agonists in patients with obesity and heart failure with preserved ejection fraction: A systematic review and meta‐analysis of randomised controlled trials
por: Armando Talavera, et al.
Publicado: (2025)

Safety, pharmacokinetics and pharmacodynamics of multiple‐dose noiiglutide ( SHR20004 ), a novel GLP ‐1 receptor agonist, in Chinese obese subjects without diabetes mellitus
por: Yang Zou, et al.
Publicado: (2024)

Suicidality among users of glucagon‐like peptide‐1 receptor agonists: An emerging signal?
por: Darren Lau, et al.
Publicado: (2024)

Prevalence of SGLT2 inhibitor and GLP1 receptor agonist prescriptions in type 2 diabetes patients with and without chronic kidney disease: Analysis of an Australian primary care dataset
por: Hannah Wallace, et al.
Publicado: (2025)

The safety, tolerability, pharmacokinetics and pharmacodynamics of an optimized dual GLP ‐1/ GIP receptor agonist ( BGM0504 ) in healthy volunteers: A dose‐escalation Phase I study
por: Yuxin Fan, et al.
Publicado: (2025)

Long‐term delirium and survival outcomes in patients treated with GLP ‐1 receptor agonists versus metformin in type 2 diabetes: A population‐based cohort study
por: Mingyang Sun, et al.
Publicado: (2025)

iGlarLixi : A titrateable fixed‐ratio combination of basal insulin + GLP‐1 receptor agonist—An effective type 2 diabetes treatment option in China
por: Miao Yu
Publicado: (2025)

Safety and efficacy of glucagon‐like peptide‐1 (GLP‐1) receptor agonists in patients with weight regain or insufficient weight loss after metabolic bariatric surgery: A systematic review and meta‐analysis
por: Ali Esparham, et al.
Publicado: (2024)